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We are presenting a case of falsely elevated T3 levels in a patient due to interference from monoclonal immunoglobulins. A 56year-old, clinically euthyroid man referred to the endocrinology clinic of the Aga Khan university, Karachi Pakistan, for possible
T3 thyrotoxicosis after thyroid function tests revealed total T3 >12.32 nmol/L (reference range 0.6–2.79), normal TSH, and total
T4 level. There was a mismatch in clinical and laboratory parameters and preliminary laboratory results were suggestive of thyroid
binding globulin abnormalities. Further evaluation in this context unmasked multiple myeloma. The presence of monoclonal
immunoglobulins can lead to assay interference and spurious results. To the best of our knowledge, this is the second case defining
the cause of falsely elevated T3 levels, due to assay interferences with binding of T3 only to monoclonal immunoglobulins.

1. Introduction
As stated in the text book of clinical chemistry, “the clinical
chemist confronted with an immunoassay result which does not
appear to fit the clinical picture and perhaps also confronted
with an alarmed physician should consider the possibility of a
phantom in the immunoassay” [1]. The above statement refers
to the spurious results which may be caused by interferences.
For the routine evaluation of thyroid function, analysis of
thyrotropin (TSH), thyroxine (T4), and triiodothyronine (T3)
are widely used diagnostic methods. However, they are subjected to nonspecific bindings that can interfere with the
measurement of these hormones. Literature review revealed
only one case till date that descripted the presence of a
monoclonal immunoglobulin in the serum or urine, which may
exhibit binding to T3 only and lead to falsely elevated results [2].

2. Case Presentation
Our patient is a 56-year-old man, who was referred from
primary care physician for elevated T3 and possible T3

thyrotoxicosis. For the past few weeks, he had been complaining of fatigue, lethargy, and weight loss. On further
evaluation, he had no diarrhea, heat intolerance, skin or hair
changes, tremors, visual changes, and palpitations. Furthermore, there was no known personal or family history of
thyroid disease. Physical exam was unremarkable except for
palpable nodular goiter, and the patient was clinically
euthyroid.
In context of fatigue, his primary care physician ordered
thyroid function tests, which showed TSH 1.67 μIU/mL
(reference range 0.5–8.9), total T3 > 12.32 nmol/L (reference
range 0.6–2.79), total T4 4.5 μg/dL (4.6–10.5), free T4
1.08 ng/dL (reference range 0.89–1.76), and free T3 of
2.4 ng/mL (reference range 2.1–4.4). The patient was referred to the endocrinologist clinic for further evaluation
The thyroid function test performed on the Siemens Advia
centaur analyzer were rechecked, but similar results were
obtained. The Siemens Advia centaur T3 assay is a two-site
Sandwich/competitive immunoassay using direct chemiluminescent technology. T3 in the patient sample competes
with a T3 analog, which is covalently coupled to
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paramagnetic particles in the solid phase for a limited amount
of acridinium ester-labeled monoclonal mouse anti-T3 antibody in the reagent. Furthermore, the same sample was
assayed using Abbot Architect Total T3 assay, and results were
>8.0 nmol/L. The Architect total T3 assay is a two-step immunoassay to determine the presence of total T3 in human
serum and plasma using chemiluminescent microparticle
immunoassay technology. This raised the suspicion of a
possible endogenous interferent in the sample.
Additional laboratory studies revealed normal liver and
renal function tests, negative hepatitis panel. The biochemical parameters are enlisted in Table 1.
As the TSH levels were not suppressed, only raised total
T3 level raised the suspicion for thyroid binding protein
abnormality. To eliminate the possible interference generated by endogenous antibodies from multiple myeloma,
serum of the patient was mixed with an equal proportion of
polyethylene glycol (PEG) 6000, i.e., 200 μl. Alongside, a
normal control serum was also precipitated with the PEG to
ensure that the T3 was not precipitated. The solution was
incubated at 37°C during 10 min and then centrifuged for 10
minutes at 5000 rpm. Total T3 activity was reassessed within
the supernatant, and result was 0.82 nmol/L (reference range
0.6–2.79), i.e., within the normal reference range. Furthermore, the IgG levels which were 113.45 g/L (normal range:
6.5–16 g/L) at baseline declined to 0.74 g/L (normal range:
6.5–16 g/L) posttreatment with PEG.
However, the anti-mouse antibody blocking analysis and
the linearity study with dilution to confirm the interference
could not be carried out because we did not have enough
baseline serum of the patient to carry out the analysis. However,
the patient stated that he had no previous exposure to mice.
Serum protein electrophoresis (SPE) was undertaken
which showed gamma globulin of 7.78 g/dL (0.5–1.6) with
an M-spike, consistent with diagnosis of multiple myeloma
and serum immunofixation (IFE) revealed IgG lambda
monoclonal gammopathy as shown in (Figure 1).
Bone marrow examination showed cellular areas with
diffuse infiltration with plasma cells (90–95%). Plasma cells
positive for CD138 and CD56. Skeletal survey was positive
for multiple lytic lesions. All findings were consistent with
diagnosis of multiple myeloma.
As the patient was clinically and biochemically euthyroid,
total T3 was falsely elevated which was determined to be due
to the excess gamma globulins interference in serum with T3
only, and the case was further referred to hematologist for
appropriate management. The patient underwent treatment
for multiple myeloma as per the recommended protocol
based on cyclophosphamide, bortezomib, and dexamethasone. The IgG levels which were 113.45 g/L (normal range:
6.5–16 g/L) at baseline normalized to 11.35 g/L (normal range:
6.5–16 g/L) posttreatment. Furthermore, the total T3 levels
posttreatment were 1.25 nmol/L (reference range 0.6–2.79).

3. Discussion
Nearly, more than 99% of both total T3 and T4 are bound to
either the thyroxine-binding globulin (TBG), transthyretin
(TTR), or albumin. The remnant fraction is the hormonally
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Table 1: Biochemical workup.
Hemoglobin
9.1 g/dl (normal range: 12.3–16.6 g/dl)
Hematocrit
28.9% (normal range: 38.4–50.7%)
7.8 × 109/L (normal range:
White blood cell count
4.8–11.3 × 109/L)
296 × 109/L (normal range:
Platelets
154–433 × 109/L)
IgG
113.45 g/L (normal range: 6.5–16 g/L)
Serum creatinine
0.9 mg/dl (normal range: 0.9–1.3 mg/dl)
Beta-2-microglobulin
6020 ng/ml (1210–2700 ng/ml)
Serum calcium
9.9 mg/dl (8.6–10.2 mg/dl)

active free hormone [3]. The routinely used total T3 and T4
immunoassays quantitate both the free and bound forms.
Keeping this fact in mind, any degree of change in these binding
proteins will result in change in the serum concentration of total
T3 and T4, generating spurious results creating a dilemma for
diagnosticians in the presence of normal TSH levels.
TBG abnormalities are usually suspected the cause when
an endocrinologist encounters a patient with elevated T4 or
T3 with normal TSH and the free forms of the hormone.
TBG excess is primarily hereditary or it can be secondary to
excess estrogens, hepatitis and certain medications 5-fluorouracil, opiates. [4, 5]. In our case, the history does not
comprise any medication known to alter TBG levels
alongside a negative hepatitis panel. Furthermore, hereditary
excess TBG production was ruled out as the patient had
previously normal thyroid function tests. Additionally,
autoantibodies to T3 or T4 have also serve as thyroid
hormone binding proteins and can falsely alter the levels of
T3 and T4 [6]. However, as the prevalence of anti-T3 or antiT4 antibodies among healthy individuals is very rare, it was
not further evaluated.
In the 90s, a case of factitious hyperthyroxinemia, due to
a monoclonal IgA kappa multiple myeloma was reported
with falsely elevated total T3 and T4 not correlating with a
normal TSH and free form of both the hormones [7]. In our
case, there was absence of any clinical evidence suggesting
abnormal TBG, so the high total T3 is most likely justified by
the monoclonal immunoglobulin identified on serum protein electrophoresis and immunofixation, binding T3 with
high affinity but not T4, as T4 levels were within normal
limits. Furthermore, as the Advia Centaur immunoassay is a
competitive binding assay, the tracer total T3 binding to the
assay antibody follows an inverse relationship with the
patient’s total T3 levels, i.e., it will eventually decline as the
patient’s serum T3 levels go up (Figure 2). In the scenario of
the monoclonal antibody interfering with the tracer binding,
a significantly elevated total T3 would be expected. This is
based on the fact that the T3 including the tracer T3 would
bind more poorly. Based on this phenomenon, an erroneously elevated T3 was evident in this case. Since the concentration on the architect was also elevated, but other
immunoassays based on different working principle were
not explored and the possibility of interference with the
other assays cannot be ruled out.
To the best of our knowledge, till date, only one similar case
with interference with only T3 has been reported by Antonopoulou et al. with euthyroid hyper-tri-iodothyronemia. In
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Figure 1: Serum protein electrophoresis showing the M-spike and serum immunofixation (IFE) results consistent with IgG lambda
monoclonal gammopathy.

Correct results
(a)

Falsely high results
(b)

Figure 2: Crossreactions by interferents in two-site immunoassay. (a) Antibodies bind to specific analyte: correct result obtained; (b) crossreactant sharing two epitopes in common with analyte: falsely high results obtained.

this case, the high total T3 was revealed to be due to the high
monoclonal immunoglobulin level, binding T3 with high affinity but not T4, as evident by normal T4 levels revealing a
diagnosis of multiple myeloma [2].

4. Conclusion
Our case report is only the second till date suggesting that
monoclonal immunoglobulins from multiple myeloma may
exhibit binding with higher affinity to T3 only leading to
falsely elevated T3 levels in euthyroid patients. It is noteworthy to recognize that spurious results of total thyroid
hormones in presence of normal TSH could be due to interferences and requires thorough evaluation based on appropriate clinical history and laboratory workup.
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